Rocconi RP, Monk BJ, Walter A, Herzog TJ, et al. Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer. Gynecol Oncol 2021 Mar 11. pii: S0090-8258(21)00229.
PMID: 33715892